The expert team of NeoAgro visited MoMed Biotech and jointly discussed the new blueprint for cooperation.
A delegation of experts from Zhejiang NeoAgro Chemical Co., Ltd. visited our company
and had in-depth technical exchanges with Bai Chen, the chairman of MoMed Biotech, to explore the possibilities of future cooperation.
On December 12, 2024, Mr. Zhang Jianrong, a director of Zhejiang NeoAgro Chemical Co., Ltd., Mr. Song Zhongshu, a scientist, Dr. Zeng Jiamei from the R & D department, and Ms. Xu Danqian from Zhejiang University of Technology visited MoMed Biotech for exchange and guidance. Mr. Bai Chen, the chairman of MoMed Biotech, together with Ms. Zhu Xiaohong, the R & D director, and Mr. An Ke, the operation director, extended a warm welcome to them.
After the brief visit, the two parties immediately held a discussion and exchange. Chairman Bai Chen gave a brief introduction to the basic situation and development of MoMed Biotech, and elaborated on its core technology research and development capabilities and the comprehensive R & D services it can provide. The expert team of NeoAgro Chemical affirmed the professional strength of MoMed Biotech.
During the subsequent discussion, the two parties carried out in-depth technical exchanges to explore the possibilities of future cooperation, hoping to achieve breakthroughs at the intersection of agriculture and biomedicine and jointly promote the progress of the industry.
END
NeoAgro (www.xnchem.com), founded in 1981, is a national key high-tech enterprise integrating scientific research, development, production and marketing. It was listed on the Shenzhen Stock Exchange on December 5, 2018. The company is committed to developing green pesticides that are highly effective, low-toxic, safe and environmentally friendly, as well as pesticide and pharmaceutical intermediate products with high-tech features. It has now established three product manufacturing bases in Xianju and Jiaojiang of Zhejiang Province and Rudong of Jiangsu Province, and a marketing, R & D and management & operation center based in Hangzhou.
MoMed Biotech (www.momed.com.cn) is the world's first biotechnology company that conducts innovative drug research and development by taking the mechanism research of drug targets as the driving force and combining advanced artificial intelligence technology. MoMed uses the Nobel Prize-winning computational biology method to study the working mechanism of target proteins, thus achieving a methodological leap at the AI data end. The MechGen drug research and development platform of MoMed Biotech integrates the industry-leading computational biology and AI drug design technologies, providing a variety of preclinical drug discovery services for the industry.
分享:
Hot News
- 2023-11-03
- 2024-04-12
-
2024-04-16
MoMed Biotech Tiantai Visit: Deepening Cooperation and Seeking Development Together
- 2024-09-30